Stock Events

Plus Therapeutics 

$1.81
25
+$0.04+2.26% Today

Statistics

Day High
-
Day Low
-
52W High
3.21
52W Low
0.97
Volume
25,375
Avg. Volume
42,571
Mkt Cap
10.32M
P/E Ratio
-0.56
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12AugExpected
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Next
-1.91
-1.31
-0.72
-0.12
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PSTV. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

About

Health Technology
Biotechnology
Manufacturing
Surgical and Medical Instrument Manufacturing
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
Show more...
CEO
Marc Hedrick
Employees
20
Country
US
ISIN
US72941H4002
WKN
000A2PPX6

Listings